logo
‘A disaster for all of us': US scientists describe impact of Trump cuts

‘A disaster for all of us': US scientists describe impact of Trump cuts

Yahoo12 hours ago
'Our ability to respond to climate change, the biggest existential threat facing humanity, is totally adrift,' said Sally Johnson, an Earth scientist who has spent the past two decades helping collect, store and distribute data at Nasa (National Aeronautics and Space Administration) and Noaa (National Oceanic and Atmospheric Administration).
Donald Trump's assault on science – but particularly climate science – has led to unprecedented funding cuts and staff layoffs across federally funded agencies and programs, threatening to derail research tackling the most pressing issues facing Americans and humanity more broadly. A generation of scientific talent is also on the brink of being lost, with unprecedented political interference at what were previously evidence-driven agencies jeopardizing the future of US industries and economic growth.
Johnson was among scores of scientists conducting vital research across a range of fields from infectious diseases, robotics, education, computer science and the climate crisis, who responded to a Guardian online callout to share their experiences about the impact of the Trump administration's cuts to science funding.
Many said they had already had funding slashed or programs terminated, while others fear that cuts are inevitable and are beginning to search for alternative work – either overseas or outside science. So far, the cuts have led to a 60% reduction in Johnson's team, and fear is mounting over the future of 30 years of climate data and expertise as communities across the country are battered by increasingly destructive extreme weather events.
'We won't be able to afford to continue providing the free and quality tools and services to make our data stores searchable, viewable, usable, and accessible. We might not even be able to afford to keep all the data … this will mean worse forecasts and less effective search and rescue responses leading to unnecessary and avoidable loss of life,' said Johnson (not her real name).
Trump's One Big Beautiful Bill Act (Obbba) calls for a 56% cut to the current $9bn National Science Foundation (NSF) budget, as well as a 73% reduction in staff and fellowships – with graduate students among the hardest hit.
The NSF is the premier federal investor in basic science and engineering, and more than 1,650 grants have also been terminated, according to Grant Watch, a non-profit tracking federally funded research grants under the Trump administration. At the behest of Trump, the hardest hit are studies aimed at addressing the unequal impact of the climate crisis and other environmental hazards, as well as any projects perceived to have a connection to diversity, equity or inclusion (DEI).
An anthropologist who researches the impact of floods and cyclones on public health and food supplies in Madagascar, which is among the most vulnerable nations in the world to the climate crisis but contributed virtually nothing to the catastrophe, is leaving Johns Hopkins for Oxford University after funding for the remainder of her fellowship was threatened.
Related: Scientists warn US will lose a generation of talent because of Trump cuts
'I am devastated to leave family, friends and the grad students I am mentoring in the US, but this seemed like the only way to continue work I've been pursuing for 10+ years. I am working on improving climate mitigation and adaptation in an African country. After Trump was elected, the writing was on the wall. There is no way I can write grant applications that will be acceptable to this government.'
A veteran infectious diseases researcher at Ohio State University was forced to abandon a clinical trial for a new medication to treat hypoxemic respiratory failure in Covid patients after the National Institute of Health (NIH) terminated funding midway through the study.
The decision will save $500,000, but $1.5m had already been spent on the trial which researchers hoped would lead to new treatment options for the million or so people hospitalized with respiratory failure each year as a result of flu, Covid and other infections. The trial would have to be repeated from the start, in order to seek approval from the FDA.
'This is a disaster for all of us. We're all depressed and living on a knife-edge, because we know we could lose the rest of our grants any day. These people really hate us yet all we've done is work hard to make people's health better. A flu pandemic is coming for us, what's happening in cattle is truly scary and all we have is oxygen and hope for people,' said the Ohio scientist.
Between 90 and 95% of their lab work is funded through the NIH. So far, more than 3,500 grants have been terminated or frozen by the NIH. Trump's budget proposes slashing NIH funding by more than 40%.
The majority of scientists who got in touch described feeling anxious and despondent – about their own work if the cuts continue, but also about what seems an inevitable loss of talent and knowledge which could upend the US position as a global leader in scientific endeavors and ricochet for years to come.
The brain drain is real. The Australian Academy of Science is leading the country's efforts to proactively recruit top US-based scientists, creating a new global talent program that includes research funding, access to Australian research infrastructure, fast-track visas and a relocation package. At least 75 scientists applied in the first three months of the program, the AAS told the Guardian.
The Trump administration has accused universities, without evidence, of promoting leftwing radical thinking and research, but federal funds train scientists who go on to work for the oil and gas, mining, chemical, big tech and other industries.
Several respondents said the private sector was also starting to feel the knock-on effect of Trump's cuts and tariffs. Wessel van den Bergh, a materials scientist with a PhD, was working on battery storage technology for a Chinese-owned renewable energy company in Massachusetts. He was laid off in early June amid Trump's tariff chaos and attacks on science and renewables, and is struggling to find work.
'When I started my PhD program, America was at the leading edge of batteries/energy storage but this is no longer true due to tariffs, funding cuts, and aggression towards green alternatives. Rather, the US has ceded its hard-earned expertise to other countries such as Korea, Japan and China,' Van den Bergh said.
Trump supports the expansion of fossil fuels and has received millions of dollars in campaign donations from the oil, gas and coal industry, while his budget legislation terminated incentives for solar and wind energy.
'It's crushing, I don't see a clear path ahead any more. I no longer feel this country values science. It's genuinely heartbreaking to build your vocation to something that could genuinely benefit the world for it to be quashed for imagined political victories … especially at a time where these kinds of technologies are the only way out of the climate crisis,' said Van den Bergh.
Separately, the Nuclear Physics Laboratory (NPL) at the University of Illinois got in touch after the Guardian's recent investigation into the chaos at the NSF. For almost 100 years the NPL has been at the forefront of cutting-edge science in drug discovery, cancer treatments, PET scans and other medical diagnoses, and semiconductor testing, with researchers playing a key role in world-renowned institutions like Cern and Los Alamos. It's a major hub for nurturing and training future talent, and at least 50 students have graduated with PhDs in the past 20 years.
It was here that Rosalind Yalow got her PhD in nuclear physics in 1945, and then went on to invent radioimmunoassay – a technique to detect minute amounts of hormones, viruses and drugs in the blood which revolutionized medical testing for conditions such as diabetes. Yalow was awarded the Nobel prize in 1977, only the second woman to win it.
The lab was recently informed that the NSF will reduce funding that supports graduates students from $15m for four years to $1m for one year.
'Our group in nuclear physics at Illinois actually predates the founding of the NSF in 1950, and we have a long history of both producing scientists and accelerator technologies that have had an impact on huge numbers of people,' said Anne M Sickles, professor of nuclear physics.
'If you cut the funding to the people who are doing the work right now, you don't know what they would have innovated in 10 years or 15 years or 32 years like Rosalind Yalow. We don't know what we're losing.'
The NFS declined to comment, while the office of management and budget and NIH did not respond.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula

Yahoo

time18 minutes ago

  • Yahoo

Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula

Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pope Leo XIV marks 56th anniversary of moon landing with observatory visit, call to Buzz Aldrin
Pope Leo XIV marks 56th anniversary of moon landing with observatory visit, call to Buzz Aldrin

Boston Globe

time20 minutes ago

  • Boston Globe

Pope Leo XIV marks 56th anniversary of moon landing with observatory visit, call to Buzz Aldrin

This was Pope Leo's first visit to the observatory, founded in 1891 by Leo XIII. The first vision of it, however, can be traced back to the establishment by Pope Gregory XIII of a commission aimed at studying the scientific data and implications of the calendar reform that took place in 1582. Advertisement The Vatican Observatory has generated top-notch research from its scientist-clerics, drawing academics to its meteorite collection, which includes bits of Mars and is considered among the world's best. Later Sunday, the pope called astronaut Buzz Aldrin, who shared with Neil Armstrong and Michael Collins the historic 1969 moonwalk. 'This evening, 56 years after the Apollo 11 moon landing, I spoke with the astronaut Buzz Aldrin,' Pope Leo, the first U.S. born Pope, wrote on his X account. 'Together we shared the memory of a historic feat, a testimony to human ingenuity, and we reflected on the mystery and greatness of Creation.' Pope Leo then blessed the astronaut, his family and his collaborators. Aldrin, 95, is the last living astronaut of the historic Apollo 11 mission. He earned a doctorate in astronautics from the Massachusetts Institute of Technology. Advertisement There are a few precedents of papal calls to 'space.' In 2011, Pope Benedict XVI rang the space station and asked about the future of the planet and the environmental risks it faced. Before Benedict, Pope Paul VI sent a radio message to astronauts Armstrong, Aldrin and Collins after their moonwalk, calling them 'conquerors of the Moon.' Although Armstrong was the first to set foot on the moon, Aldrin followed him down the ladder of the Eagle Lander. 'He gazed at the lunar landscape and spontaneously remarked to Houston, 'Beautiful, beautiful. Magnificent desolation,' according to Aldrin's official website. FILE - The reflections of astronaut Neil Armstrong, the U.S. flag, the lunar module and a television camera are seen in the face mask of astronaut Edwin "Buzz" Aldrin when his picture was made by Armstrong as they walked across the surface of the moon, July 20, 1969. (Neil Armstrong/NASA via AP, File) Neil Armstrong/Associated Press

Study reveals this type of exercise lowers your biological age by 9 years
Study reveals this type of exercise lowers your biological age by 9 years

Yahoo

time31 minutes ago

  • Yahoo

Study reveals this type of exercise lowers your biological age by 9 years

When you buy through links on our articles, Future and its syndication partners may earn a commission. If you're looking to pause time, we've got good news — when it comes to biological aging, that's the aging process that happens inside your cells, sweating can help. Specifically, sweating due to high-impact exercise, which can lower your biological age by nearly a decade, according to researchers. The study, conducted at Brigham Young University and published in the Preventive Medicine medical journal, looked at the data of more than 5,800 adults aged 20-84. The study looked at the participants' biological age by examining the length of their telomeres — these are the protective DNA caps at the end of chromosomes. Telomeres prevent your DNA from getting damaged; they shorten as we get older, and shortened telomeres are often associated with age-related diseases. The measurement is taken through blood samples. The researchers found that people who consistently performed high levels of physical activity, specifically high-impact activity, had longer telomeres than those with sedentary lifestyles. For the study, to be highly active, women had to engage in 30 minutes of jogging per day and 40 minutes for men, five days a week. They concluded that regular high-impact exercise added nine years of reduced cellular aging. 'If you want to see a real difference in slowing your biological aging, it appears that a little exercise won't cut it,' exercise science professor Larry Tucker said. 'You have to work out regularly at high levels.' If you're new to jogging, it can be difficult to know where to start. Mixing jogging with walking intervals as you get fitter and build up your distance, also known as Jeffing, can be beneficial. Here's everything you need to know about Jeffing, and a round-up of the best running shoes on the market. That said, if you're not a runner or you're worried about the impact of running on your joints, high-intensity training doesn't have to involve pounding the sidewalk or hours on the treadmill. HIIT training, cycling sprints on a stationary bike, taking a spin class, or using the rowing machine in the gym all count as high-intensity exercise. Find the one that works for you, and you'll increase your cardiovascular fitness while lowering your biological age. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Forget running and swimming — study finds this sport adds 10 years to your life Forget gym machines — study shows this type of exercise is the most effective at building strength, muscle and power Forget 10,000 steps — study reveals the real number of minimum daily steps you should take, according to your age

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store